<DOC>
	<DOC>NCT00871572</DOC>
	<brief_summary>This drug is being evaluated for possible treatment of type 2 diabetes mellitus. Participation in this study is expected to last up to 18 weeks. A goal of this study is to determine the safety and effectiveness of LY2409021.</brief_summary>
	<brief_title>A Study for Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Inclusion: Patients must either be male, or a female who cannot become pregnant, who has type 2 diabetes and is either controlling your diabetes through diet and exercise alone, or with diet and exercise taking metformin. If Patients are male, Patients are willing to talk to the study doctor about birth control options during the study and for 3 months after the last dose of study medication. Patients must have an Hemoglobin A1c (HbA1c) test of 6.5% to 10% Patients must have a body mass index (BMI) between 25 to 40 kg/m2. Patients must be willing and able to test your blood sugar levels at home with a blood sugar meter. Patients must complete a study diary as instructed by your study doctor and staff and return the study diary as instructed by the study doctor. Patients must maintain consistent dietary, physical activity, and sleeping patterns throughout the study. Insulin, exenatide, or any diabetic medication other than metformin 3 months prior to screening to control you diabetes, Medications to increase movement in your digestive tract or that slow movement in your digestive tract Overthecounter drugs or drugs prescribed by your doctor that cause weight loss or high or low blood sugar, Chronically use oral glucocorticoids therapy or have received this type of medication within 8 weeks prior to beginning this study, Class II and III antiarrythmic agents (commonly used to prevent or relieve an irregular heartbeat), Drugs that damage the liver Fibrates and niacin (both commonly used to treat high cholesterol) more than 1 gm/day, Central nervous stimulants, alcohol intake for males that is more than 2 units per day and for females that is more than 1 unit per day (1 unit=12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits). You have had one (1) or more cases of uncontrolled diabetes (very high blood sugars) which required hospitalization in the 6 months prior to the screening visit or have a diagnosis of hypoglycemia (low blood sugar) unawareness. You had two (2) or more emergency room visits or were hospitalized for poor control of your diabetes (for example, ketoacidotic episode) in the last 6 months. Patients have a problem with your stomach such that it empties slowly (diabetic gastroparesis) or you have had gastric bypass (bariatric) surgery. Patients have a personal or family history of pancreatic neoplasia. Patients have abnormal lipids (for example triglycerides). Patients have had problems with your heart in the past 6 months, such as a heart attack, chest pain (angina), heart failure, heart bypass operation, angioplasty (a medical procedure to open a narrow or clogged blood vessel of the heart) or stent insertion (a procedure to insert a wire mesh tube to prop open a blood vessel after angioplasty), a heart rhythm problem, or a stroke. Patients have an elevated or uncontrolled blood pressure. Patients electrocardiogram (ECG, a test that measures the electrical activity of your heart) is outside the normal limits, as determined by the study doctor. Patients have a problem with your kidneys or are on dialysis. Patients have a problem with your pancreas. Patients must not have nor had liver disease (for example, Hepatitis B or C). Patients have cancer, except for skin cancer or have been in remission (the absence of disease activity) from cancer for less than 5 years. Patients have a serious or uncontrolled health problems (other than type 2 diabetes), blood disorders or laboratory tests that in the opinion of the doctor, could interfere with understanding the results of this study. The doctor will let you know if this applies to you. Patients previously completed or withdrew from this study or any other study investigating LY2409021. Patients are allergic to the study drug or other related drugs. You cannot be in this study if you are a woman and you possibly could become pregnant during this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Diabetes Mellitus, Type 2</keyword>
</DOC>